Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Results for Anorexia Nervosa with Psilocybin.

2.

What Do Patients Want Doctors to Know About Breast Cancer Recurrence?

3.

For MDS-Related Anemia, Telomerase Inhibitor Approved.

4.

NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.

5.

We Don't Always Know What's 'Best' for Our Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot